Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Dexmedetomidine-esketamine for Depression and Anxiety in Ureteral Reconstruction
NCT07753772Phase 4Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 4 trial of dexmedetomidine, esketamine in major depressive disorder (MDD), anxiety disorder, sponsored by Peking University First Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
dexmedetomidineesketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT07753772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753772.